What's Happening?
Gilead Sciences and Amgen have initiated significant investments in new U.S. facilities. Gilead is developing a manufacturing hub in Foster City, California, as part of a $32 billion investment plan, while Amgen plans to invest over $600 million in a new science and innovation center in Thousand Oaks, California. These investments aim to enhance U.S. biopharma innovation and create thousands of jobs, responding to pressures to onshore manufacturing.
Why It's Important?
The investments by Gilead and Amgen reflect a strategic shift towards strengthening U.S. biopharma capabilities, driven by pressures to reduce reliance on imported medicines. These developments are expected to boost innovation, create jobs, and enhance the U.S.'s position in global biopharma leadership. The focus on advanced digital infrastructure and automation highlights the industry's move towards cutting-edge technologies.
